Julia Hardick, M.Sc.
Position: PhD Student
Room no.: CP-02-110
Telephone no.: +49 (0)231 755 7053
Member of the group since: 11/2015
University degree: M.Sc. in Chemical Biology, TU Dortmund University
Earlier positions: Bachelor and master studies in the group of Daniel Rauh on the MAPK p38α
Expertise: organic synthesis, pharmacokinetics (drug metabolism studies)
Off-Lab activities (hobbies): badminton, inline skating
The research project contains structure-based design, organic synthesis and the determination of synthesized compounds in a pharmacokinetic context, such as the identification of metabolic stability in a phase I metabolism assay as well as plasma stability.
Regarding the synthesis part of my work I focused on Her2, a member of the human epidermal growth factor receptor family, which overexpression has been shown to act as a key player in breast cancer. A second synthesis project deals with the mitogen activated protein kinase kinase 7 (MKK7) and the evaluation of covalent inhibitors to target the JNK-pathway. Both kinases represent attractive targets in drug discovery and offer fascinating medicinal chemistry projects.
- Kaitsiotou, H., Keul, M., Hardick, J., T. Mühlenberg, T., Ketzer, J., Ehrt, C., Krüll, J., Medda, F., Koch, O., Giordanett, F., Bauer S., Rauh D., Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT. J Med Chem, 2017, 60(21):8801-15.
- Bührmann, M., Hardick, J., Weisner, J., Quambusch, L., Rauh, D., Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Angew Chem Int Ed Engl, 2017, 56(43):13232-36.
- Bührmann, M., Wiedemann, B. M., Müller, M.P., Hardick, J., Ecke, M., Rauh, D., Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PLoS ONE, 2017, 12(9):e0184627.